Subscribe
shutterstock_1155148972_atmosphere1
Atmosphere1 / Shutterstock.com
22 November 2022AmericasStaff Writer

MSD makes $1.4bn bid on biopharma company

Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More on this story

Generics
MSD hit with €39m fine over contraceptive generic delay
26 October 2022   The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.
Big Pharma
Big pharma co buys $16.6bn for heart tech company
2 November 2022   Cardiovascular ‘innovator’ snapped up as company strengthens medtech offering | Massachusetts-based Abiomed will become part of purchaser’s medtech division
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York